ABIOMED Financial Statements (ABMD)
|
|
|
|
Report date
|
|
|
24.05.2018 |
23.05.2019 |
21.05.2020 |
21.05.2021 |
20.05.2022 |
|
03.11.2022 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
593.7 |
769.4 |
840.9 |
847.5 |
1 032 |
|
1 074 |
|
Operating Income, bln rub |
|
|
157.1 |
224.8 |
249.2 |
229.6 |
372.7 |
|
253.6 |
|
EBITDA, bln rub |
? |
|
164.5 |
230.8 |
257.5 |
246.9 |
500.5 |
|
469.8 |
|
Net profit, bln rub |
? |
|
112.2 |
259.0 |
203.0 |
225.5 |
136.5 |
|
266.8 |
|
|
OCF, bln rub |
? |
|
192.5 |
252.2 |
314.9 |
274.6 |
285.4 |
|
251.0 |
|
CAPEX, bln rub |
? |
|
55.9 |
44.0 |
44.0 |
53.4 |
35.8 |
|
33.8 |
|
FCF, bln rub |
? |
|
136.7 |
208.2 |
270.9 |
221.2 |
249.6 |
|
217.2 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
|
|
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
338.0 |
415.1 |
440.4 |
456.1 |
586.9 |
|
619.4 |
|
Cost of production, bln rub |
|
|
98.6 |
129.6 |
151.3 |
161.9 |
188.2 |
|
200.6 |
|
R&D, bln rub |
|
|
75.3 |
93.5 |
98.8 |
121.9 |
163.4 |
|
167.2 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
49.8 |
|
94.2 |
|
|
Assets, bln rub |
|
|
786.4 |
1 054 |
1 216 |
1 494 |
1 673 |
|
1 697 |
|
Net Assets, bln rub |
? |
|
689.5 |
936.9 |
1 065 |
1 330 |
1 503 |
|
1 540 |
|
Debt, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Cash, bln rub |
|
|
362.2 |
491.7 |
443.1 |
583.7 |
758.6 |
|
820.4 |
|
Net debt, bln rub |
|
|
-362.2 |
-491.7 |
-443.1 |
-583.7 |
-758.6 |
|
-820.4 |
|
|
Ordinary share price, rub |
|
|
|
|
145.2 |
318.7 |
331.2 |
|
381.0 |
|
Number of ordinary shares, mln |
|
|
44.2 |
44.9 |
45.2 |
45.1 |
45.4 |
|
45.4 |
|
|
Market cap, bln rub |
|
|
0 |
0 |
6 558 |
14 387 |
15 053 |
|
17 288 |
|
EV, bln rub |
? |
|
-362 |
-492 |
6 115 |
13 804 |
14 295 |
|
16 467 |
|
Book value, bln rub |
|
|
637 |
889 |
1 011 |
1 204 |
1 381 |
|
1 417 |
|
|
EPS, rub |
? |
|
2.54 |
5.77 |
4.49 |
5.00 |
3.00 |
|
5.88 |
|
FCF/share, rub |
|
|
3.10 |
4.64 |
6.00 |
4.90 |
5.49 |
|
4.79 |
|
BV/share, rub |
|
|
14.4 |
19.8 |
22.4 |
26.7 |
30.4 |
|
31.2 |
|
|
EBITDA margin, % |
? |
|
27.7% |
30.0% |
30.6% |
29.1% |
48.5% |
|
43.7% |
|
Net margin, % |
? |
|
18.9% |
33.7% |
24.1% |
26.6% |
13.2% |
|
24.8% |
|
FCF yield, % |
? |
|
|
|
4.13% |
1.54% |
1.66% |
|
1.26% |
|
ROE, % |
? |
|
16.3% |
27.6% |
19.1% |
17.0% |
9.08% |
|
17.3% |
|
ROA, % |
? |
|
14.3% |
24.6% |
16.7% |
15.1% |
8.16% |
|
15.7% |
|
|
P/E |
? |
|
0.00 |
0.00 |
32.3 |
63.8 |
110.3 |
|
64.8 |
|
P/FCF |
|
|
0.00 |
0.00 |
24.2 |
65.0 |
60.3 |
|
79.6 |
|
P/S |
? |
|
0.00 |
0.00 |
7.80 |
17.0 |
14.6 |
|
16.1 |
|
P/BV |
? |
|
0.00 |
0.00 |
6.49 |
12.0 |
10.9 |
|
12.2 |
|
EV/EBITDA |
? |
|
-2.20 |
-2.13 |
23.7 |
55.9 |
28.6 |
|
35.1 |
|
Debt/EBITDA |
|
|
-2.20 |
-2.13 |
-1.72 |
-2.36 |
-1.52 |
|
-1.75 |
|
|
R&D/CAPEX, % |
|
|
134.8% |
212.5% |
224.4% |
228.3% |
456.9% |
|
495.3% |
|
|
CAPEX/Revenue, % |
|
|
9.41% |
5.72% |
5.23% |
6.30% |
3.47% |
|
3.14% |
|
| ABIOMED shareholders |
